Targeting XPNPEP1 for Cancer Treatment (G7511)

Target Name: XPNPEP1

NCBI ID: G7511

XPNPEP1

Targeting XPNPEP1 for Cancer Treatment

XPNPEP1 ( short for X-linked positive selectin protein-1 ) is a protein that is expressed in human tissues and is associated with various diseases, including cancer. It is located on the X chromosome and is a key regulator of cell adhesion and migration.

Recent studies have identified XPNPEP1 as a potential drug target for cancer treatment. By inhibiting the activity of XPNPEP1, researchers have found that they can reduce the growth and spread of cancer cells. This is because XPNPEP1 plays a role in the development and maintenance of cancer cells, and by blocking its function, researchers can kill or inhibit the growth of these cells.

One of the challenges in targeting XPNPEP1 is its high levels of expression in many different tissues and cells. However, researchers have found that inhibiting the activity of XPNPEP1 using small molecules or antibodies can be effective in preclinical studies. These studies have shown that blocking XPNPEP1 can significantly reduce the growth of cancer cells in a variety of models, including mouse models of breast cancer and lung cancer.

Another potential challenge with targeting XPNPEP1 is its involvement in various signaling pathways. XPNPEP1 has been shown to be involved in several signaling pathways, including the TGF-β pathway and the Wnt pathway. Disrupting these signaling pathways could be difficult and may require additional targeting agents to achieve effectively.

Despite these challenges, researchers are actively pursuing the development of drugs that target XPNPEP1. Many of these drugs are in the pipeline and are being tested in clinical trials. Some of these drugs are designed to inhibit the activity of XPNPEP1 directly, while others are targeting it indirectly through inhibiting other proteins that are involved in its signaling pathway.

In conclusion, XPNPEP1 is a protein that is associated with various diseases, including cancer. It is located on the X chromosome and plays a key role in the development and maintenance of cancer cells. In recent years, researchers have found that XPNPEP1 is a potential drug target for cancer treatment, and many ongoing studies are focused on developing drugs that inhibit its activity. Further research is needed to fully understand the effects of XPNPEP1 targeting and to develop safe and effective drugs.

Protein Name: X-prolyl Aminopeptidase 1

Functions: Metalloaminopeptidase that catalyzes the removal of a penultimate prolyl residue from the N-termini of peptides, such as Arg-Pro-Pro (PubMed:11106490, PubMed:35165443, PubMed:18515364). Contributes to the degradation of bradykinin (PubMed:11106490)

The "XPNPEP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XPNPEP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets